Storm doses first patient with solid tumour drug candidate
Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development
Read More
Tag: solid tumour
Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
